Cytokinetics (CYTK) Accumulated Expenses (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Accumulated Expenses of $27.4 million for Q1 2026, down 36.91% year-over-year from $43.4 million in Q1 2025, and down 39.41% quarter-over-quarter from $45.2 million in Q4 2025.
Cytokinetics (CYTK) Accumulated Expenses (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Accumulated Expenses for 17 consecutive years, with $27.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses fell 36.91% year-over-year to $27.4 million; the TTM figure through Mar 2026 stood at $27.4 million (down 36.91% YoY), while the FY2025 annual figure was $45.2 million, up 28.52% from the prior year.
- Accumulated Expenses eased to $27.4 million in Q1 2026 per CYTK's latest filing, from $45.2 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $52.3 million in Q2 2025 and bottomed at $12.5 million in Q2 2022.
- Historically, Accumulated Expenses has averaged $31.7 million across 5 years, with a median of $31.5 million in 2023.
- Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 321.88% — and 2023, when it tumbled 53.68%.
- Cytokinetics' Accumulated Expenses stood at $21.8 million in 2022, then surged by 95.9% to $42.6 million in 2023, then fell by 17.61% to $35.1 million in 2024, then increased by 28.52% to $45.2 million in 2025, then tumbled by 39.41% to $27.4 million in 2026.
- Business Quant data shows CYTK's Accumulated Expenses at $27.4 million in Q1 2026, $45.2 million in Q4 2025, and $33.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76.86 Mn |
| Mar 31, 2026 | 27.36 Mn |
| Dec 31, 2025 | 45.15 Mn |
| Sep 30, 2025 | 33.20 Mn |
| Jun 30, 2025 | 52.32 Mn |
| Mar 31, 2025 | 43.36 Mn |
| Dec 31, 2024 | 35.13 Mn |
| Sep 30, 2024 | 27.88 Mn |
| Jun 30, 2024 | 20.00 Mn |
| Mar 31, 2024 | 40.12 Mn |
| Dec 31, 2023 | 42.64 Mn |
| Sep 30, 2023 | 22.35 Mn |
| Jun 30, 2023 | 31.47 Mn |
| Mar 31, 2023 | 13.66 Mn |
| Dec 31, 2022 | 21.77 Mn |
| Sep 30, 2022 | 40.23 Mn |
| Jun 30, 2022 | 12.52 Mn |
| Mar 31, 2022 | 29.48 Mn |
| Dec 31, 2021 | 34.37 Mn |
| Sep 30, 2021 | 11.75 Mn |